Activation of the aryl hydrocarbon receptor by methyl yellow and related congeners: Structure-activity relationships in halogenated derivatives

Biological and Pharmaceutical Bulletin

Volumn 25, Issue 4, 2002, Pages 466-471

  Kato, Taka Aki ^a   Matsuda, Tomonari ^b   Matsui, Saburo ^b   Mizutani, Takaharu ^a   Saeki, Ken Ichi ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Aryl hydrocarbon receptor; Azocompound; Halogenated derivative; Methyl yellow; Structure activity relationship

Indexed keywords

2',4' DICHLOROBENZANILIDE; 4 DIMETHYLAMINOAZOBENZENE; 4' CHLOROBENZANILIDE; ANILIDE; AROMATIC HYDROCARBON RECEPTOR; AZOBENZENE; BENZANILIDE; CHLORINE DERIVATIVE; LIGAND; STILBENE; UNCLASSIFIED DRUG; DRUG DERIVATIVE;

ARTICLE; HALOGENATION; MOLECULE; STRUCTURE ACTIVITY RELATION; CHEMISTRY; DOSE RESPONSE; HUMAN; METABOLISM; SACCHAROMYCES CEREVISIAE;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; P-DIMETHYLAMINOAZOBENZENE; RECEPTORS, ARYL HYDROCARBON; SACCHAROMYCES CEREVISIAE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036545570     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.25.466     Document Type: Article

References (29)

1. Pohjanvirta R., Tuomisto J., Pharmacol. Rev., 46, 483-549 (1994).
2. Gonzalez F. J., Fernandez-Salguero P., Drug Metab. Dispos., 12, 1194-1198 (1998).
3. Okey A. B., Riddick D. S., Harper P. A., Trends Pharmacol. Sci., 15, 226-232 (1994).
4. Schmidt J. V., Bradfield C. A., Ann. Rev. Cell. Biol., 12, 55-89 (1996).
5. Jones P. B. C., Galeazzi D. R., Fisher J. M., Whitolock J. P., Jr., Science, 277, 1499-1502 (1985).
6. Gonzalez F. J., Tukey R. H., Nebert D. W., Mol. Pharmacol., 26, 117-121 (1984).
7. Sutter T. R., Tang Y. M., Hayes L. L., Wo Y. Y. P., Jabs E. W., Li X., Yin H., Cody C. W., Greenless W. F., J. Biol. Chem., 269, 13092-13099 (1994).
8. Talakowski-Hpokins C. A., King R. G., Pickett C. B., Proc. Natl. Acad. Sci. U.S.A., 85, 1000-1004 (1988).
9. Favereau L. V. Pickett C. B., J. Biol. Chem., 266, 4556-4561 (1991).
10. Lamb J. G., Straub P., Tukey R. H., Biochemistry, 33, 10513-10520 (1994).
11. Vasiliou V., Kozak C. A., Lindahl R., Nebert, D. W., DNA Cell Biol., 25, 235-245 (1996).
12. Levine W. G., Drug Metab. Rev., 23, 253-309 (1991).
13. Stiborová M., Frei E., Schmeiser H. H., Wiessler M., Hradec J., Curcinogenesis, 13, 1657-1662 (1992).
14. Miller J. A., Miller E. C., Adv. Cancer Res., 1, 339-396 (1953).
15. Garner R. C., Martin C. N., Clayson D. B., "Chemical Carcinogens, 2nd edn." ACS Monograph 182, Vol. 1, ed. by Searle C. E., American Chemical Soc., Washington DC, 1984, pp. 175-302.
16. Kimura T., Kodama M., Nagata C., Kamataki T., Kato R., Biochem. Pharmacol., 34, 3375-3377 (1985).
17. Degawa M., Kanazawa C., Hashimoto Y., Carcinogenesis, 3, 1113-1117 (1982).
18. Yamazaki H., Degawa M., Funae Y., Imaoka S., Inui Y., Guengerich F. P., Shimada T., Carcinogenesis, 12, 133-139 (1991).
19. Shimada T., Iwasaki M., Martin M. V., Guengerich F. P., Cancer Res., 49, 3218-3228 (1989).
20. Cheung Y.-L., Puddicombe S. M., Gray T. J. B., Iosnnides C., Carcinogenesis, 15, 1257-1263 (1994).
21. Safe S. H., Ann Rev. Pharmacol. Toxicol., 26, 371-399 (1986).
22. Miller C. A. III, J. Biol. Chem., 272, 32824-32829 (1997).
23. Miller C. A. III, Martin M. A., Hyman L. E., Nucleic Acids Res., 26, 3577-3583 (1998).
24. Miller C. A. III, Toxicol. Appl. Pharmacol., 160, 297-303 (1999).
25. Adachi J., Mori Y., Matsui S., Takigami H., Fujino J., Kitagawa H., Miller C. A. III, Kato T., Saeki K., Matsuda Y., J. Biol. Chem., 276, 31475-31478 (2001).
26. Kennedy S. W., Lorenzen A., Jones S. P., Hahn M. E., Stegeman J. J., Toxicol. Appl. Pharmacol., 141, 214-230 (1996).
27. Jones J. M., Anderson J. W., Environ. Toxicol. Pharmacol., 7, 19-26 (1999).
28. Giller M., Bergman J., Cambillau C., Fernström B., Gustafsoon J.-Å., Mol. Pharmacol., 28, 357-363 (1985).
29. Gillner M., Bergman J., Cambillau C., Alexandersson M., Fernstoröm B., Gustafsson J.-Å., Mol. Pharmacol., 44, 336-345 (1993).